- Home
- KELYA vs MREO Comparison
KELYA vs MREO Comparison
Compare KELYA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KELYA
- MREO
- Stock Information
- Founded
- KELYA 1946
- MREO 2015
- Country
- KELYA United States
- MREO United Kingdom
- Employees
- KELYA N/A
- MREO N/A
- Industry
- KELYA Professional Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- KELYA Consumer Discretionary
- MREO Health Care
- Exchange
- KELYA Nasdaq
- MREO Nasdaq
- Market Cap
- KELYA 403.0M
- MREO 424.5M
- IPO Year
- KELYA N/A
- MREO N/A
- Fundamental
- Price
- KELYA $11.72
- MREO $2.15
- Analyst Decision
- KELYA Buy
- MREO Strong Buy
- Analyst Count
- KELYA 1
- MREO 7
- Target Price
- KELYA $25.00
- MREO $7.71
- AVG Volume (30 Days)
- KELYA 296.3K
- MREO 943.2K
- Earning Date
- KELYA 05-08-2025
- MREO 05-13-2025
- Dividend Yield
- KELYA 2.56%
- MREO N/A
- EPS Growth
- KELYA N/A
- MREO N/A
- EPS
- KELYA N/A
- MREO N/A
- Revenue
- KELYA $4,451,600,000.00
- MREO N/A
- Revenue This Year
- KELYA $9.31
- MREO N/A
- Revenue Next Year
- KELYA $4.14
- MREO $54.91
- P/E Ratio
- KELYA N/A
- MREO N/A
- Revenue Growth
- KELYA N/A
- MREO N/A
- 52 Week Low
- KELYA $10.80
- MREO $1.58
- 52 Week High
- KELYA $23.81
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- KELYA 45.63
- MREO 40.94
- Support Level
- KELYA $11.37
- MREO $2.12
- Resistance Level
- KELYA $12.08
- MREO $2.27
- Average True Range (ATR)
- KELYA 0.33
- MREO 0.13
- MACD
- KELYA -0.04
- MREO -0.02
- Stochastic Oscillator
- KELYA 24.14
- MREO 9.09
About KELYA Kelly Services Inc.
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).